THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT

: Jackowski et al.

INVENTION

: Biopolymer Marker Indicative Of Disease State Having A Molecular Weight Of 1998 Daltons

SERIAL NUMBER

: 09/846,346

FILING DATE

: April 30, 2001

EXAMINER

: Gabel, Gailene

CERTIFICATE UNDER 37 CFR 1.8(a)

GROUP ART UNIT

: 1641

OUR FILE NO.

: 2132.013

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450 on

Mail Stop: Non-Fee Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

DECLARATION UNDER 37 CFR § 1.132

- I, George Jackowski, do hereby declare as follows:
- 1. I am one of the named inventors of the application entitled "Biopolymer Marker Indicative of Disease State Having A Molecular Weight of 1998 Daltons", having U.S. Application Serial No. 09/846,346, filed April 30, 2001.
- 2. In the Office Action mailed on August 24, 2004, claims 36-40, (as originally presented) were rejected under 35 U.S.C. 112, first paragraph because the claimed invention allegedly contains subject matter which was not described in the specification in such McHale & Slavin P.A. 2132.013 -Declaration 37 CFR 1.132 Page 1 of 3

a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The claims (as currently amended) have been limited to an isolated biopolymer marker having SEQ ID NO:1 (the 1998 dalton marker) useful in methods for determining the presence of the biopolymer marker. The method of the invention as recited in claim 36 involves confirming the presence of the isolated biopolymer marker having SEQ ID NO:1 in the patient sample wherein the presence of the biopolymer marker is indicative of a link to Type II diabetes.

- 3. The data provided in attached Appendix A was originally filed in Applicant's application no. 09/846,330, now Pub. No. U.S. 2002/0160420, both applications were filed on April 30, 2001. The data further clarifies the identification of SEQ ID NO: 1 in serum samples of patients being evidentiary of Type II diabetes sampled from patients suffering from a variety of disease states, see page All of Appendix A.
- 4. This declaration (including the attached Appendix A) is provided in order to show data obtained from a clinical trial involving over 500 patients suffering from a variety of disease states, see page 32 lines 9 to 15 of Pub. No. U.S. 2002/0160420. The patient specific samples and data are used to formulate a library of proteomic materials having characteristics identifiable with both normal and abnormal physiological conditions or predictive hallmarks thereof. The data on page All of Appendix A indicates the patients from which the isolated biopolymer marker MCHale & Slavin P.A. 2132.013 -Declaration 37 CFR 1.132 Page 2 of 3

consisting of SEQ ID NO:1 (the 1998 dalton marker) was confirmed are linked to Type II diabetes. This Appendix A does not represent results obtained from additional experimentation. This data was obtained in the original experiments performed at the time of the invention.

The undersigned declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the Application or any patent issuing thereon.

MN 19 2004

George Jackowski

\\Ms2\client files\2100-2199\2132 -Syn-X\2132_000013 - Marker 1998\Amendmen:\$\2132_013_132_appendix.wpd



	Sequence	G)DFL AEGGGVR/G)	G)DFL AEGGGVR(G)	(G)DFLAEGGGVR(G)	E)GDFLAEGGGVR(G)	E)GDFI AFGGGVR/G)	E)GDFLAEGGGVR(G)	(E)GDFL AFGGGVR(G)	E)GDFL AFGGGVR/G)	(D)PEVRPTSAVAA(-)	(D)PEVRPTSAVAA(-)	(D)PEVRPTSAVAA(_)	(D)PEVRPTSAVAA(-)	(D)PEVRPTSAVAA(-)	(D)PEVRPTSAVAA(-)	G)EGDFLAEGGGVR(G)	G)EGDFLAEGGGVR(G)	G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR/G)	(G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	(G)EGDFLAEGGGVR(G)	G)EGDFLAEGGGVR(G)	GDFLAEGGGVR(G)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	ł	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	H)RIHWESAS(L(R)
	Protein Name										Apolipoprotein (D	Apolipoprotein (D																		Complement C3f (H)												Complement C3f (H)
	MW								1077	1097	1097	1097	1097	1097	1097	1206	1206	1200	1206	1206	1206	1206	1206	1206	1206	1211 Comp					_				1211	1171	1211	1171	1211	1211	1211	1211
	UISBASB	IM:	W	Ž.	N. C.	W	V	2		1			Į.	-	l ybe II Diabetes	Donal Fallure	Donal Failure	Done Fell	Donot Collection	Agilai rail	Kenal Failure	o i d	Sis	Vols	renysis Keno	IVI XIIIJE			IW	×	¥	M	Σ		Str		-	Stake I	CA) Stroke ICL	9		
Patient History	Σ				Ž	Acute MI SK222	Novew C-don	TVII 'mi passa	Rectal blood Asthma NIDDM	M. MINON	A.fib. Diahetes smoker UTN	, levolis (concern)	A.fib. Diabetes smoker H									Unstable andina hamodial	Unstable anding hemoretical	Rapid atrial Fib. Prior Hy CAN beamed		GE (gastroesophageal) ref	Inferior MI, Hiatal Hemia	MI, NIDDM							Acute CVA, Basal ganglia	HTN, previous CVA, CVA (R MCA) used tPA	CVA, transfer to VA	HIN ICH	Prior CVA, acute CVA (L MC	HTN, acute CVA (R subcortical	HTN, Diabetes, acute CVA (Riparietal)	
er Age	65	_		77	58	52	65		67	77	62	73	62		82	- 67	77	80	92	20	92	99	89	8	77	65	20	92	28	52	92				5 4	72	47	26	72	72	67	
Gender	≥			L	Σ	Σ	Σ		ıL	ц	Σ	Σ	Σ		Σ	ட	ц.	Σ	Σ	ш.	և	Σ	Σ	u.	u.	Z	L	щ	Σ	Σ	Σ				ш	Σ	Σ	Σ	Σ	Σ	L	
Code #	SJ CON 07	HNS-SJ28	HNS-SJ33	SJ CON 06	SJ CON 17	SJ CON 19	SJ CON 21	HNS-SJ28	SJ CON 05	SJ CON 06	TWH-039	184-988	TWH-039	184-988	SJ CON 01	SJ CON 05	SJ CON 06	SUCON 09	KO NOO CS	SJ CON 10	SJ CON 14	SJ CON 04	SJ CON 11	SJ CON 13	SJ CON 06	SJ CON 07	SJ CON 10	SJ CON 14	SOON 17	87 CON 19	SO CON Z	7700-011	8700-00IU	SSCO-ONIE	CU-15	CU-18	CU-19	CU-30	CU-33	CU-37	CU-38	

	- 11	(H)RIHWESASLL(R)	(H)KIHWESASLL(R)	(T)KIHWEGASIL(K)	(1) KINWESASIL(K)	(H)KIHWESASLL(K)	(T) MINITING ASTER (T)	(A) KINWEGASTL(K)	(H)KIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	(H)RIHWESASLL(R)	_ 11	(H)RIHWESASLL(R)		(H)RIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)															
Drotein Namo		Complement Car	Complement Cat	Complement C3f	Complement Cat	Complement C3f	Complement C3f	Complement Cat	Complement Cal	Complement Con	Complement Car	Complement Car	Complement Car	Complement Car	Complement Car	Complement	Complement	Complement C31	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f				
WW	1244	1211	1211	1211	1211	1211	1211	1211	1211	1244	1244	127	1211	101	1211	1211	1244	1244	17,00	1	17.		1348	348	1348	1348	1348	1348	1348	240	240	1348	1348	240	1348	1348	1348	1348	1348	1348	348	1348
Disease	CAF	CHF	岩	붕	불	당	CHF	岩	CH	#5°	H.	#5 #5	#E	HZ.	AHC.	HE CHE	DE SE						IVII	IVI	IMI	W	M	M	IV.	IVI	MI	Otroko IO	Ottoke-ICH	Stroke-ion	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke ICH	OIIONE-ICH
Patient History	STAGE 3	STAGE 3	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE3 - DEAD	STAGE 3	STAGE 3	STAGE 3	STAGE 3	Acute MI - STAGE 3		STAGE 4	STAGE 3	STAGE 3	STAGE 3	STAGE 3	STAGE 3	STAGE 3	STAGE 3			Hemodialveis	hemodialveis	Sievinorion.						ICH, secondary to AVM	HOI	Acute CVA Basal gapolia	HTN 10th the limit	THE CONTROL OF A PARTY OF THE P	OVA + COA (R MCA) used (PA			HTN. acute CVA (R subcortical	HTN. Diabetes, acute CVA /B pagately	לוביום ומיון בתוכן לוביום ומיום
er Age	61	65	29	75	77	65	67	67	79	8	43	45	59	99	51	8	59	9/	51	62	70	77	65	20	92	58	52	92				69	44	2	99	2	47	29	72	72	29	
Gender			_	L	<u> </u>	L.	∑ :	Σ	Σ	Σ	Σ	Σ	Σ	ц.	Σ	Σ	Σ	ட	Σ	Σ	Σ	ட	Σ	ட	ட	Σ	Σ	Σ				L	L	ட	Σ	Σ	. ≥	Σ	Σ	Σ	L	
Code #	23604 - KKB	23707 - KL	22/03 - MMS	20206 - MM	22103 - GM	21813 - GR	23008 - GFB	23402 - HM	20208 - HIF	22803 - HB	23616 - JGK	20803 - EW	23421 - FB	22813 - CL	23130 - ER	23105 - FC	23116 - FC	20414 - EYG	23130 - ER	23134 - FC	20102 - EAB	SJ CON 06	SJ CON 07	SJ CON 10	SJ CON 14	SJ CON 17	SJ CON 19	SJ CON 21	HNS-SJ22	HNS-SJ28	HNS-SJ33	69-NO	CU-12	CU-15	CU-10	CU-18	CU-19	CU-30	CU-33	CU-37	CU-38	

		R)	R)	3)	(R)	R)	R)	3	(R)	٦)	٦)	3	(R)	2	2	7	2	3)	3	۲)	۲)	3)	(2	(>	(2	(<u>G</u>)	(9)	(<u>O</u>)	(0)	(<u>o</u>)	(<u>o</u>	(S)	(<u>0</u>	(<u>0</u>	(<u>©</u>	(<u>0</u>	(9)	9	رَ	- 0
	Sequence	(T)HRIHWESASLL(R)	(I)HRIHWESASLL(R		(I)HRIHWESASLL(I	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(F	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)		(T)HRIHWESASLL(F	(T) IN HWESASLL(R)	(1) HRIHWESASLL(R)	T) TIME OF STREET	(1) TRIHWESASLL(K)	(1)HRIHWESASLL(R)	(I)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R)	(T)HRIHWESASLL(R	(T)HRIHWESASLL(R	(D)SESDFLAEGGGVR(G	(D)SESDFLAEGGGVR(G)	(D)SESDFLAEGGGVR(G	(D)SESDFLAEGGGVR(G	(D)SESDFLAEGGGVR(G	(D)SESDFLAEGGGVR/G	(D)SESDFLAEGGGVR/G								
	Protein Name	Complement C3f	Complement C3	Complement Cat	Completifient	Complement Cst	Complement C3f	Complement Cor	Complement C31	Complement C3f	Complement C3f	Complement Con	Complement Cat	Complement C3f	Complement C3f	Complement C3f	Complement Cat	Complement Cat	Complement Col	Complement Car	Complement Car	Complement C3f	Connipiement Cat	Complement C3f	Complement C3f	Alpha Fibrinogen	Alpha Fibrinogen	Aipna Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen						
VA/A/	V 2 4 0	1348	1348	1348	1348	13/0	1348	13/0	1340	13/0	1348	19/0	1348	1348	1348	1348	1348	1348	1348	1348	13/8	1348	1240	340	0 50	1350	1350	2000	1350	250	1350	1550	200	020	000	1350	1350	1350	1350	
Disease	Stroke-ICH	Stroke-ICH	Stroke-ICH	FS	HZ.	H.	15 15 15 15 15 15 15 15 15 15 15 15 15 1	분	E S	35	붕	분	당	분	CAF	CHF	붕	CHE	CHE	CHE	H.	HS.	u L	3 2	Bonol Foilure	Ranal Failure	MI	Donol Eathur	Ranal Eallura	MI alluid	Panal English	Mi	Donot Follows	Milairailaie	IVI	Renal Fallure	N.	M	IM.	
Patient History	HTN, Prior CV	HTN, Prior CVA, CVA	HTN, Prior CVA, ICH	STAGE 3	STAGE 3	STAGE 3		STAGE 3	STAGE 3	STAGE3 - DEAD	STAGE 3	STAGE 3	STAGE 3	STAGE 3	Acute MI - STAGE 3	STAGE 3	STAGE 4	STAGE 3																						
Gender Age	64	49	43	91	65	67	75	77	65	- 67	67	79	8	5	45	200	8	21	8	29	76	51	62	70	82	29	77	77	8	92	92	20	20	65	65	28	52	65		
Gend	Σ	Σ	Σ	Σ	<u>.</u>	ı	ഥ	L	ட	Σ	Σ	≥	≥:	Σ :	≥ 2	≥L	-	∑ :	Σ	Σ	ᇿ	Σ	Σ	Σ	Σ	ட	щ	ட	Σ	Σ	Σ	L.	F	L	L.	Σ	Σ	Σ		
Code #	09-DO	99-00	57-02	23504 - KKB	23/07 - KL	22703 - MMS	20206 - MM	22103 - GM	21813 - GR	23008 - GFB	23402 - HM	20208 - HIF	22803 - HB	20010 - JUN	23424 EB	22842	22400 - 01	23130 - ER	23105 - FC	23116 - FC	20414 - EYG	23130 - ER	23134 - FC		SJ CON 01	SJ CON 05	SJ CON 06:	SJ CON 06:	STCON-09	SJ CON 07	SJ CON 07	SJ CON 10	SJ CON 10	SJ CON 14	SJ CON 14	SJ CON 17	SJ CON 19	SJ CON 21.	HNS-SJ22	

	Sequence	(D)SESDFLAEGGGVR(G)	(D)SESDFLAEGGGVR(G)	(D)SESUFLAEGGGVR(G)	(R)DAHKSEVAHKFK(D)	(A)DAHASEVAHKFK(D)	(R)DAHKSEVAHKFK(D)	(R)DAHKSEVAHRFK(D)	(i)THRIHWESASLL(R)	(I)THRIHWESASI I (R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)													
Drotein Name	Alpho Elbring	Alpha Fibringen	Alpha Fibrinogen	Sering Albumin	Series Albumin	Serim Albumin	Similar Minimo	Social Modernia	Serum Albumin	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C31	Complement C3f													
×Μ	1350	1350	1350	1406	1406	1406	1406	140g	904	400	1406	400	1406	400	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	9449	1448	1440	244	24/4	4440	P .	449	1449	1449	1440	2440	1443
Disease	Renal failure	Renal failure	Renal failure	CHF	送	SF	CFF	HZ.		בול	ביים כיים	בוב	ביים ל		Mil	IMI	IMI	W	W	W.	₩.	Ž	W.	W.	Otroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH	Stroke-ICH Stroke ICH	Stroke-ICH	Stroke ICE	Stroke ICL	Ollohollo Ollohollo Ollohollo	Stroke-101	Stroke IC	Ottoba-10-1	Stroke-ICI	Coloxe-ICH	Stroke-ICH	CHE		בור
Patient History	Unstable angina, hemodialysis		Rapid atrial Fib, Prior Hx CAN hemodialysis	Acute MI - STAGE 3	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE 3	STAGE 3	STAGE	STAGE 3	STAGE3											ICH secondary to AVM	ואואר טו לושטיים ליינים	Acute CVA Basel	HTN ICH dobt theimic	HTN acute CVA	HTN. ICH (gerebellar vermis)		CVA. transfer to VA	HJN. ICH	HIN ICH	Prior CVA, acute CVA (L MCA)	HTN, acute CVA (R subcortical	HTN. Diabetes, acute CVA (B. padete)	HTN. Prior CVA. ICH (R thalamic hemorrhane)	HTN Prior CVA CVA	HTN. Prior CVA ICH	STAGE 3	STAGE 3	
ar Age	99	99	80	45	29	99	51	64	59	76	51	62	70	77	65	20	65	28	52	95				69	44	54	99	20	9/	72	47	55	56	72	72	29	4	49	43	61	92	
Gender	Σ	Σ	ш	Σ	Σ	L	Σ	Σ	Σ	ů.	Σ	Σ	Σ	ц.	Σ	ட	u	Σ	≥	Σ				щ	L	L	Σ	Σ	L	Σ	Σ	Σ	Σ	Σ	Σ	tL.	Σ	Σ	Σ	Σ	Œ	
Code #	SJ CON 04	SJ CON 11	SJ CON 13	20803 - EW	23421 - FB	22813 - CL	23130 - ER	23105 - FC	23116 - FC	20414 - EYG	23130 - ER	23134 - FC	20102 - EAB	SJ CON 06	SJ CON 07	SJ CON 10	SJ CON 14	SJ CON 17	SJ CON 19	SJ CON 21	HNS-SJ22	HNS-SJ28	F.NS-S.J33	69-NO	CU-12	CU-15	CU-10	CU-14	CU-16	CU-18	CU-19	CU-28	CU-30	CU-33	CU-37	CU-38	09-NO	CU-66	CU-75	23604 - KKB	23707 - KL	

	Sequence	(I)THRIHWESASLL(R)	(I)THRIHWESASI L(R)	(I)THRIHWESASLL(R)	(I)THRIHWESAS[L(R)	(I)THRIHWESASLL(R)	1	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASLL(R)	(I)THRIHWESASI I (B)	(I)THRIHWESASLI (R)	(I)THRIHWESASLL(R)	(I)THR(HWESASLL(R)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(A)DSGEGDFLAEGGGVR(G)	(T)ADSGEGDFLAEGGGVR(G)	(T)ADSGEGDFLAEGGGVR(G)	(T)ADSGEGDFL AFGGGVR/G)	(R)DAHKSEVAHRFKD(I)	(R)DAHKSEVAHRFKD(L)	(R)DAHKSEVAHRFKD(L)	(R)DAHKSFVAHREKD(I)												
	Protein Name	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Alpha Fibrinogen	Serum Albumin	Serum Albumin	Serum Albumin	Serum Albumin													
	MIM.	1449	4448	0 0 7 7	244	D 7 7 7	644	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1449	1465	1465	1465	1465	1465	1465	1465	1400	1400	400	204-7	400	1400	402	1465	1518	1518	1518	1521	1521	1521	1521
	Disease	ב ב	E E	ES SEC			110	는 !	ES	CHF	CHF	7 2	± 15	7 5	분.	± 15	노	SH	H S	± 1	Kenal Failure	Renal Fallure	Kenal Fallure	Renai Failure	Relial Fallure	Popul Callure	Donal failure	Donal failure	Renal failure	Stroke IOL	Stroke IC	Strokeric	Ottoko-lori	Stroke-ICH	Olloke-ICH	W	W	W.	Renal Failure	Renal Failure	Kenal Failure	Kenal Failure
Patient History			STAGE 3	STAGE 3	STAGE3 - DEAD	STAGE 3	STAGE 3	STOCE STATE	S TOYES	i c	OTOTO STORY	STAGE	STAGE 3	STACES	STACES	STACE 3	STACES	STACES	STAGE 3	2 100.0							Unstable angina, hemodialveis	Unstable angina, hemosdialvsis	Rapid atrial Fib, Prior Hx CAN hemodialveis		HTN, ICH right thalmic	HTN, ICH (cerebellar vermis)	HTN. acute CVA (R subcortical	HTN. Diabetes, acute CVA (R pariotal)	(in parietal)							
er Age	29	75	77	65	67	29	79	9	43	45	29	99	51	2	59	9/	2.	63	2	82	67	12	8	92	29	65	99	89	80	44	99	92	72	29	65	20		83	29	12	8	
Gender	, F	L.	L.	ш	Σ	Σ	Σ	Σ	Σ	Σ	Σ	L.	Σ	Σ			Σ	Σ	Σ	Σ	L.	u	Σ	Σ	ц.	Ŀ	Σ	¥	ц.	ட	Σ	ււ	Σ	ட	Σ	LL.		Σ	u	ı	Σ	
Code #	22703 - MMS	20206 - MM	22103 - GM	21813 - GR	23008 - GFB	23402 - HM	20208 - HIF	22803 - HB	23616 - JGK	20803 - EW	23421 - FB	22813 - CL	23130 - ER	23105 - FC	23116 - FC	20414 - EYG	23130 - ER	23134 - FC	20102 - EAB	.SJ CON 01	SJ CON 05	SJ CON 06	STCON 09	SJ CON 07	ST 60110	SJ CON 14	SJ CON 04	SJ CON 11	SJ CON 13	CU-12	CU-10	CU-16	CU-37	CU-38	SJ CON 07	SJ CON 10	HNS-SJ22	SJ CON 01	SJ CON 05	SJ CON 06	SJ CON 09	

Miles Mile		Protein Name Sequence	(R)DAH	Serum Albumin (R)DAHKSEVAHRFKD(L)	Serum Albumin (R)DAHKSEVAHRFKD(L)							(T)ADSOCOST. STOCK	ADSCECULIAEGGG				Complement C3f (K)ITHRIHW/FSAS11/P)				(K)ITHRIHWESAS!				(K)ITHRIHWESASI I		(K)ITHRIHWESASLL			Complement C3f (K)ITHRIHWESASLL(R)	Complement C3f (K)ITHRIHWESASLL(R)	Complement Cat (K)ITHRIHWESASLL(R)		(K)ITHRIHWESASLL		(K)I HRIHWESASLL		LE LA		
Gender Age Patient History M 66 Unstable angina, hemodialysis F 66 Unstable angina, hemodialysis F 66 Unstable angina, hemodialysis F 66 Sapid atrial Flb, Prior Hx CAN hemodialysis F 65 Sapid atrial Flb, Prior Hx CAN hemodialysis F 65 Sapid atrial Flb, Prior Hx CAN hemodialysis F 65 Sapid atrial Flb, Prior Hx CAN hemodialysis F 65 Sapid atrial Flb, Prior Hx CAN hemodialysis F 65 Sapid atrial Flb, Prior Hx CAN hemodialysis F 65 Sapid Barial Flb, Prior Hx CAN hemodialysis Sapid Barial Flb, Prior Hx CAN hy		+	\dagger	+	†	\dagger	\dagger	1										1							1		+													
Gender Agender Amagender Amagender<	-		Rena	Rena	vsis	Vele	dialysis	Cleryon	N	V	V	V	N	Λ	N.	V	N N	W	W	M	3		200						STAGE 3			3								
		7	20	65	99	89	8	20			-	77	65	20	65	28	52	92			61	. 69	29	75	7.7	65	29	67	79	8	43	£ 5	8	8 2	0 4	\$ G	26	51	62	
	Gent	_	_	4	4	4	-	L				L	. ≥	L	14	Σ	Σ	Σ			Σ			u.	u.	ц	Σ	≅ :	Σ :	≥ :	≥ 2	≥ 2	<u>≥</u> u	- 2	≦ ≥	Σ	ž lu	. ≥	Σ	

÷ -

		Ċ					
S.I CON 10	<u> </u>	8 8		ĕ	1616		Sequence
2000	+	3		₹	1010	Corribiement C3f	
1	1	8		IW	0 0	Complement C3f	
	4	28			0 0	Complement C3f	
SJ CON 19	Σ	52		IW.	1616	Complement C3f	
SJ CON 21	Σ	92		ξ W	1616	Complement C3f	
18-5,122				W	1616	Complement C3f	
HNS-SJ28				Ĭ	1616	Complement C3f	
HNS-SJ33		L		W	1616	Complement C3f	
CON 06	L	11		M	1616	Complement Caf	
CON 07		9		M	1690	Complement Cat	- 1
SJ CON 10		3 2		×	1690	Complement Cat	(S)KITHRIHWESASLL(R)
S.I CON 14		3 6		Σ	1690	Complement Co.	(S)KITHRIHWESASLL(R)
S I CON 47	- =	8		×	1,600	Complement	(S)KITHRIHWESASLL(R)
	١	ñ		W	200	Complement C3f	(S)KITHRIHWESASLL(R)
200	-	8	ICH, secondary to AVM	Stroke-IOH	000,	Complement C3f	
71-00	_	4	HO	101 01010	1090	Complement C3f	(S)KITHRIHWESASI (R)
CU-15	u .	54	Acute CVA Basal ganglia	STOKE-ICH	1690	Complement C3f	(S)KITHRIHWEGAGI (D)
CU-10	Σ	99	-1.	STOKE-ICH	1690	Complement C3f	(S)KITUDIUMITO SOLI (S)
CU-14	Σ	50	TTN Out of	Stroke-ICH	1690	Complement C3f	(S)KITUDII WESASEL(K)
CU-16	u	76		Stroke-ICH	1690	Complement C3f	(S)VITTINESASTE(R)
CU-18	Σ	72	HTN STATE CEREBONIAL VOLUNIS	Stroke-ICH	1690	Complement C3f	(S) THE HEID (R)
CU-19	Σ	47	Old CAA (R MCA) used tPA	Stroke-ICH	1690	Complement C34	(S)/NI HRIHWESASLL(R)
CU-28	2	55	CVA, transfer to VA	Stroke-ICH	1690	Complement C3f	(S)KITHRIHWESASLL(R)
CU-30	2	3 4	HIN, ICH	Stroke-ICH	1690	Complement Cat	(S)KITHRIHWESASLL(R)
011-33	2	8	HTN, ICH	Stroke-ICH	1690	Complement	(S)KITHRIHWESASLL(R)
CI 137	≥ :	7/	Prior CVA, acute CVA (L MCA)	Stroke-ICH	1600	Contibientient CSI	(S)KITHRIHWESASLL(R)
200	≥ 1	7	HTN, acute CVA (R subcortical	Stroke-ICH	1600	Complement C3f	(S)KITHRIHWESASLL(R)
99-50	_ :	6	HTN, Diabetes, acute CVA (R parietal)	Stroke-ICH	030	Complement C3f	(S)KITHRIHWESASLL(R)
00-00	≅ :	8	HTN. Prior CVA. ICH (R thalamic hemorrhage)	Stroke-ICH	1600	Complement C3f	(S)KITHRIHWESASLL(R)
90-	Σ	49	HTN, Prior CVA, CVA	Stroke-ICH	1690	Complement C3f	
e/-00	≥	43		Otroko IOI	080	Complement C3f	(S)KITHRIHWESASI (R)
23604 - KKB	Σ	61	STAGE3	EOI-BUONO FILE	1690	Complement C3f	il-
23707 - KL	ш	65	STAGE 3	בול	1690	Complement C3f	(S)KITHRIHWESASI (P)
22703 - MMS	ц.	29	STAGE 3	- L	1690	Complement C3f	(S)KITHRIHWESASI (P)
20206 - MM	u.	75	STAGE 4	Ė	1690	Complement C3f	31.
22103 - GM	u.	77	4 10010	SF	1690	Complement C3f	(S)KITUDIUM/POAGL(R)
21813 - GR	u	65	2 10 410	문	1690	Complement C3f	(S)VITUDII WITO COLLINIO
23008 - GFR	Σ	22	OI AGE 3	당	1690	Complement C3f	(S)KITHRIMESASLL(K)
23402 HM	2	3 2	SIAGE3 - DEAD	뚱	1690	Complement Cost	(S)KIIHKIHWESASLL(R)
20202	≦ :	۵	STAGE 3	CHE	1600	Contibilitient CST	(S)KITHRIHWESASLL(R)
	Σ	6/	STAGE 3	275	1090	Complement C3f	(S)KITHRIHWESASLL(R)
22803 - HB	Σ	8	STAGE 3		089	Complement C3f	(S)KITHRIHWESASI (R)
23616 - JGK	Σ	43	STAGE 3	5	1690	Complement C3f	SIKITUDIUM O VOLI (A)

:

٠	Sequence	(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASLL(R)	(S)KITHRIHWESASI (R)	(S)KITHRIHWESASI (R)	(S)KITHRIHWESASI (P)	(S)KITHRIHWESASI (P)	(S)KITHRIHWEGGE (D)	(S)KITHRIHWESASI (D)	(S)KITHDILIMES ASI (D)	(S)SKITHRIHWEGASI (B)	(S)SKITHBIHMES AS I (D)	(S)SKITHBIHWEGAGIL (B)	11_	(S)SKITHRIHWESASI (D)	(S)SKITHRIHWESASL (R)	1	(S)SKITHRIHWESASI (R)	(S)SKITHRIHWESASI (B)		(S)SKITHRIHWESASI (R)	(S)SKITHRIHWESASI (R)	(S)SKITHRIHWESASI I (R)	(S)SKITHRIHWESASLI (R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASLL(R)		S)SKITHBIII WESASLL(R)	(S)SKITHBILIMESASLL(R)	(S)SKITHRIHWESASI (B)	(S)SKITHDIUMEDADIUME	(S)SKITHRIHWESASIL(R)	S)SKITUDIUMEDASIL (R)	S)SKITUDIUMESASLL(K)	SISKITUDITIVE SASEL(R)	SJSKI THRITWESASLL(K)	S SKI I TRIHWESASLL(K)	SISKITUDIUMES SELL(R)	SONT INTERVEDIGE (R)	S/SINTINION EGASEL(R)
Oroton	riotelli ivame	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement Cat																				
Disease	+			1							-	-	┪	┥	abetes	+	+	+	abetes		1	1777	+	\dagger	Stroke ich	Stroke-ICH 4777	\dagger	\dagger	T	Stroke-ICH 1777					_			Stroke-ICH 1777	CHF 1777.	CHF 1777	CHF 1777	
Patient History	Acute MI - STAGE 3	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE 3	STAGE 3	STAGE	STAGE 3	STAGES	the learning	died of CA Dec 22/08	020			NIDDM HTN Right Angling	D .	Aphasia. Rt heminaralysis	(2)2(2)				ICH, secondary to AVM	HOI	Acute CVA, Basal ganglia			(8	used tPA	o VA	10. VIE				tal)	ormage)	¥^>	A, ICH		STAGE 3	SIAGES	
	45	29	99	51	64	59	9/	51	62	0,	82	82	67	77	77	8	81	9/	92	50	65	58	69	44	54	99	20	9/	7/	55	56	72	72	67	╁	+	43	16	2 6	67		
Gender	Σ	Σ	ı.	Σ	Σ	Σ	ц	Σ	Σ	Σ	Σ	Σ	u.	ш.	ட	Σ	Σ	Σ	Σ	L.	щ	Σ	ıL	L	L	Σ	١	T 2	ΣΣ	Σ	Σ	Σ	Σ	L	Σ	≥	≥	≥	u	L		
Code #	20003 - EW	23421 - FB	22425 - CL	23130 - ER	23105 - FC	23116 - FC	20414 - EYG	23130 - ER	23134 - FC	20102 - EAB	SJ CON 01	SJ CON 01	SJ CON 05	SJ CON 06	SJ CON 06	SJ CON 09	TWH-002	600- HM I	SUCON 07	SJ CON 10	SJ CON 14	SJ CON 17	69-NO	CU-12	CU-15	CU-10	41-00	200-100	CC-13	CU-28	CU-30	CU-33	CU-37	CU-38	09-NO	20-66	CU-75	23604 - KKB	23707 - KL	22703 - MMS		

=

	Sequence	(S)SKITHRIHWESASLL(R)	(S)SKITHRIHWESASI I (R)	(S)SKITHRIHWESASI I (R)	(S)SKITHRIHWESASI (B)	(S)SKITHRIHWESASI I (B)	(S)SKITHRIHWERARI (D)	(S)SKITHRIHWEGAGI (D)	(S)SKITHBIHWEGASI (D)	(S)SKITHDIHMESASEL(R)	(S) SKITUDIUM TO A SI : (S)	(S)SKITUBININES ASLL(K)	OSKITURIUMESASLL(K)	SOCITION SASTER	(S)SKITINITAMESASLL(R)	(S)SKITHWESASCL(R)	(S)SATITIVESASIL(R)		(S)SNITHRIHWESASLL(R)	(S)SKITIES (R)	(S)SKITHBILWESASLL(R)	(2)SNITHNIEWESASLL(R)	(+) PNOEKSHALOL NNROIR(-)	(+)RINGTRSHALOLNNROIR(-)	(+)RNGFKSHALOLNNROIR(-)	(+)RNGFRSHALQLNNRQIR(-)	(+) BNO FKSHALOLNNROIR(-)	(+) PNOFICE IN PAIR (-)	(+)ROCKTINE (-)	(+)SOKITUBILIMESASLL(R)	(+)SOKITUDILIMITO SOLITOR	(+)SOKITUDILIMITO (C.)	(+) SOKITUDILIMITO AST (F)	(+)SOVITION ESASEL(K)		(+)SSKIIHKIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASLL(R)	(+)SSKITHRIHWESASL (R)	(+)SSKITHRIHWESASLL(R)
	Protein Name	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C34	Complement C3f	Complement C3f	Complement C4 fragment	Complement C4 fragment	Complement C4 fragment	Complement C4 fragment	Complement C4 fragment	Complement C4 fragment	Complement C4 fragment	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement Cat	Complement Co.	Complement Car	Contiblement Cor	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f
3	MIN	1///)))	///	///-	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1777	1845	-	-	+-	┿-	┿-	1845	1865	1865	1865	1865	1865	1865	1865	1865	1865	1865	1886	2007	2000	200	0001
Dispass	DOBOG!	בולים ביי	בובו	בובי		5 6	5 6	÷ ;	Ė	CFF	붕	품	농	SF	유	CAF	유	농	눔	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	Type II Diabetes	W	Type II Diabetes	lype II Diabetes	Type II Diabetes	Type II Diabetes	┝	┿	+	+				
Patient History	STAGE 4	STAGE 3	STAGE 3	STAGE3 - DEAD	STAGE 3	STAGE 3	STAGE 3	STAGE 3	Acute MI - STAGE 3	u l	STAGE 3	STAGE 3	CHOCHO	SINCES	S TO YES	310015	01AGE 3	S TO THE	STAGE 3	Apparia Dit	Apriasia, N. Hemparalysis,										Hx of prostate CA home delication	Signate CA, Helfiddialysis	Complete homicagaia	Stroke BM II. NIBBIT	SHOKE, FIM HX, NIDDM, INCL BP		MOOIN	MODIN					
ar Age	75	11	92	67	- 67	79	9	43	45	59	99	51	9	20	92	2	63	2	84	76								82	1/2	77	80	81	76	63	3 6	12.	? 3	8 8	3	20	65	58	
Gender	L	u.	L	Σ	Σ	Σ	Σ	Σ	Σ	Σ	ц.	Σ	Σ	Σ	L	Σ	Σ	Σ	Σ	Σ								Σ	L	L	Σ	Σ	Σ	Σ	2	Z	≥ ≥		ΣL			Σ	
Code #	20205 - MM	22/103 - GM	21313-GR	23008 - GFB	23402 - HM	20208 - HIF	22803 - HB	23616 - JGK	20803 - EW	23421 - FB	22813 - CL	23130 - ER	23105 - FC	23716 - FC	20414 - EYG	23130 - ER	23134 - FC	20102 - EAB	TWH-002	TWH -009	TWH-002	TWH -009	TWH-024	TW/H-039	743-450	164-988	734-989	SJ CON 01	SJ CON 06	SJ CON 06	SJ CON 09	TW/H-002	TWH -009	TWH-024	TWH-039	184-988	734-989	SON OF	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	92 CON 17	

				000000			
20102 - EAB	Σ	70	STAGE 3	0.000	AMM.	Protein Name	Sequence
T/VH-002					1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
TWH -009			Complete hemianonia emoker	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
TWH-024	Σ	63	Stroke. PM Hx NIDOM inc. BD	Type II Diabetes	COR	Complement C3f	(+)SSKITHRIHWESASLL(R)
WH-039				Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
184-988	Σ	73	MOCIN	Type II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASLL(R)
734-989	Σ	92	MOOIN	ype II Diabetes	1865	Complement C3f	(+)SSKITHRIHWESASI (R)
SJ.CON 07	Σ	92	MOOR	lype il Diabetes	1865	Complement C3f	(+)SSKITHRIHWEGGS(+)
SJ CON 17	≥	58		W	1896	Complement C4A	1111
HNS-SJ22				Ĭ	1896	Complement C4A	(R)NGEKSHAI OLINIBOLD(C)
TWH-002				W	1896	Complement C4A	(D)NOEROHALOLINIAGINACIO
TWH -009				Type II Diabetes	1998	Complement C3f	(1) (1) (1) (1) (1) (1) (1) (1) (1) (1)
TWH OSA				Type II Diabetes	1998	Complement C34	(-) SOUTH TRIBANCE (-)
T/V/L 020				Type II Diabetes	1008	Complement	(+)SSKIIHKIHWESASLL(-)
800-114				Type II Diahetes	1000	Compenielli Col	(+)SSKITHRIHWESASLL(-)
743-450				Type II Dishotes	0000	Complement C3f	(+)SSKITHRIHWESASLL(-)
184-988				The Holdbergs	288	Complement C3f	(+)SSKITHRIHWESASI I (-)
734-989				ype II Diabetes	1998	Complement C3f	(+)SSKITHRIHWESASI (-)
SJ CON 01	Σ	83		1ype II Diabetes	1998	Complement C3f	(+)SSKITHBIHMS(+)
SJ CON 06	ш	11		Type II Diabetes	2021	Complement C3f	(-)OCKITEDIONICO (-)
S.I CON OR	. u	- 1-		Type II Diabetes	2021	Complement Caf	(-) OCIVITINI WESASTER(-)
SO NOO!	- -	: 6		Ξ	2021	Complement C3f	(+)SONTHRIMMESASLLR(-)
80 800	≥ :	ဥ္က		Type II Diahatas	2024	Complement	(+)SSKITHRIHWESASLLR(-)
1 WH-002	≥	84		Type II Diabetes	202	Complement C31	(+)SSKITHRIHWESASLLR(-)
600- HAA	Σ	92		Type II Dishetes	1707	Complement C3f	(+)SSKITHRIHWESASLLR(-)
T/WH-024	Σ	63		Type II Diabetes	2021	Complement C3f	(+)SSKITHRIHWESASI R/L)
T\VH-039	Σ	62		i ype II Diabetes	2021	Complement C3f	(+)SSKITHRIHWEGARI D/
184-988	Σ	73		I ype II Diabetes	2021	Complement C3f	(+)SSKITHBIHMEOACI - D/
734-989	≥	er.		Type II Diabetes	2021	Complement C3f	(+)SSKITHDIDIMEONOL DV
SJ CON 07	2	3 4		Type II Diabetes	2021	Complement C3f	(+)SCKITUDIOWEDVOI : EX
0 1 NO 1 N	<u> </u>	3 3		Ξ	2021	Complement Caf	(-)SONTINKINGSASELK(-)
2 3 3	-	3		I	2024	Complement	(+)SSKITHRIHWESASLLR(-)
SJ CON 14	щ	65		V	707	Complement C3f	(+)SSKITHRIHWESASLLR(-)
SJ CON 17	Σ	58		W	1707	Complement C3f	(+)SSKITHRIHWESASLLR(-)
CON 19	Σ	52		IIV.	5021	Complement C3f	(+)SSKITHRIHWESASLLR(-)
SJ CON 21	Σ	35		Σ.	2021	Complement C3f	(+)SSKITHRIHWESASI D/_)
HNS-SJ22				Œ	2021	Complement C3f	(+)SSKITHRIHWEGAGI D
S-S.128		\dagger	,	W	2021	Complement C3f	(+)GCKITUDIUMICOACITO
HNS-S 133		\dagger		W	2021	Complement C3f	(+)COKITUDITING VOL. D.
23604 - KKB	2	2		M	2021	Complement C3f	(-)ACIVITATION (-)
23.707 1/1	ž L	5 2	SIAGE 3	SF	2021	Complement C3f	(-) SOLITION ENABLE (-)
20, 20, 20, 20, 20, 20, 20, 20, 20, 20,	-	S	STAGE 3	CHE	2021	Complement Co.	(+)SSKITHKIHWESASLLR(-)
24/03 - MMS	-	67	STAGE 3		2024	Complement Car	(+)SSKITHRIHWESASLLR(-)
20206 - MM	11_	75	STAGE 4	Ť	1700	Complement C3f	(+)SSKITHRIHWESASLLR(-)
22103 - GM	u.	77	STAGE 3		1707	Complement C3f	(+)SSKITHRIHWESASLLR(-)
					1,707	Complement C3f	(+)SSKITHRIHWESASI I R(-)

	Sednence	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASLLR(-)	(+)SSKITHRIHWESASI I R(-)	(+)SSKITHRIHWESASI I R(-)	(+)SSKITHRIHWESAS! 1 B/-)	(+)SSKITHRIHWEGAGI G	(+)SCKITUDIUMEOVOLIDI	(+)SOKITHDIDWESASLLK(-)	(+)SOKITUBILINGS SOLD	(+)SOKITUDII IMITO SOLI E	(+)SCRITTEDITMEDASTER(-)	(+)SONITION ESASILR(-)	(+)SOKITEDIENTER ASILE (-)	(+)SSKITUDIUMESASLIK(-)	(+)SOKITUDIUMED SOLVEY	(+)SOCITUDITINGS SOCIETY	(+)SOKITHDIDIVES ASIL R(-)	(+)SCKITUDIUMITONOLLE(-)	(+)SOKITHBILWEDAGLLK(-)	(+)SSKITHBILWERABILE(-)	(+)SSKITHRIHWEGASILD()	SSKITHRIHWEGAGI D	SSKITHRIHWEGAGILD	SSKITHRIHWESASI I B	SSKITHRIHWESASLIR	SSKITHRIHWESASLLR	SSKITHRIHWESASLLR	SSKITHRIHWESASLLR	SSKITHRIHWESASLLR	SSKITHRIHWESASLLR	SSKITHRIHWESASLLR	SSKITHRIHWESASLLR	SSKITHRIHWESASLLR	SSKITHRIHWEGAGILD						
Protein Name	OH BY HEAD	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement C3f	Complement Cat	Complement Cat	Complement	Complement Car	Complement C3f	Complement C31	Complement C3f					
Disease MW	CHF 0004		1	T								CHF 2021					+	-	-	-	-	+	betes			2056 2056	1	CHE								CHE	+		1	1	+	2020
Patient History	STAGE 3	STAGE3 - DEAD	STAGE 3	STAGE 3	STAGE 3	STAGE 3	Acute MI - STAGE 3	STAGE3	STATE A	4 TO TO	STAGES	S HOVE	010010	S HOVE	STAGES	STAGE 3	0 100 0						STAGE 3	STAGE 3	STAGE 3	STAGE 4	STAGE 3	STAGE 3	STAGE3 - DEAD	STAGE 3	STAGE 3	STAGE 3	STAGE 3	Acute MI - STAGE 3	STAGE 3	STAGE 4	STAGE 3					
Celiuer Age	+	M 67	\dagger	+		+	M 45	M 59	F 66	M 51	M 64	H		M 51	\vdash	M 70							M 61		F 67	F 75		+	M 67	/9 Z	\dagger	200	+	+	1	+	†	7	+	+	M 51	
21813 - GR	23008 CEB	23402 - Gra	2020C	11L - 0000	22.2003 - HB	43016 - JGK	20803 - EW	23421 - FB	22813 - CL	23130 - ER	23105 - FC	23116 - FC	20414 - EYG	23130 - ER	23134 - FC	20102 - EAB	TWH-002	1/WH -009	TWH-024	TWH-039	184-988	734-989	23604 - KKB	23707 - KL	22703 - MMS	20206 - MM	22103 - GM	23608 OFF	בו פו	M I	+	+		ב ב ב	4	3 2	_	+	4	ב ב ב	23130 - ER	

		Sequence	CONTINUINATION	SONITURINATEDASTICK	SSKITHRIHWESASLLR	(A)TVGSLAGOPI OFRACIAMGEDI (D)	(A)TVGSI AGODI OEDAOAMOTOI (A)	(A)TYGG AGOB! CRENACHINE	(A) WORN CARACAWGERL(R)	(1) DATINGEVARK-KOLGEENFKALVL(1)	(R)DAHKSEVAHRFKDLGEENFKAI VI III	(R)DAHKSEVAHBEKNI GERNEVALVIII		(I) ON INSEVABILITY OF GEEN PRALVL(I)	(K)DAHKSEVAHRFKDLGEENFKALVI (I)	(R)DAHKSEVAHREKDI GEENEKAI VI 10/61	(R)DAHKSEVAHREKNI GEENEVALVILAKEN	(R)DAHKAEVALDEKRI OFFICE (A)	(P) P	(R)DAHKSEVAHRFKDLGEENFKALVLIA(F)	(R)DAHKSEVAHRFKDLGEENFKALVITA/F)	
	Protein Name	, totall Ivalife	Complement C3f	Complement	COTIDIE LIBERTICO	Apoliprotein E	Apoliprotein E	Apoliprotein E	Sering Albumin	1111000	Serum Albumin	Serum Albumin	Serum Albumin	Son im Albridge		Serum Albumin	Serum Albumin	Serum Albumin	Sarim Albumin		serum Albumin	
	MΚ		2056	2056	2200	/077	2267	2267	2753	2753	3 3	2/23	2753	2753	2000	7237	2937	2937	2937	2027	2007	
	Disease	11.00	FFO	품	Insulin Resistance				Insulin Resistance	Insulin Resistance		I ISUIII LESISIANCE	Insulin Resistance	Insulin Resistance	Include Decision	TOTAL PROPERTICE	Insulin Resistance	Insulin Resistance	Insulin Resistance			
Dationt Ulate	, auglit mistory	STAGE 3	CTANGE 2	S TAGE S	Insulin Resistance	Insulin Resistance	Insulin Besistans	Palipion Deleti	HISOHIL MENISTRINCE	Insulin Resistance	Insulin Resistance	Instilio Recietanos	BOILDISING TO THE STATE OF THE	Instill Resistance	Insulin Resistance	Insulin Resistance	Insulin Resistance	Ineulia Docieta	History Nesistance	Insulin Resistance		
Age		95	70	٠	-	۷	2	c	c	- 0	,	٢	c	. 0	1	~	7	2	٠			
Gender Age	2	Σ	≥	2	<u> </u>	-	LL.	Σ	Σ	L		ıL.	ı	2	Ž	Σ	щ	LL.	ш			
Code #	23134 EC	J - 1010.	20102 - EAB	3111898	44.0000	1,2096	5124698	3111898	42698	112500	12030	0101600	5124698	3111808		42698	112698	6101600	5124698			